AU2006326727A1 - Means and methods for the treatment of tumorous diseases - Google Patents

Means and methods for the treatment of tumorous diseases Download PDF

Info

Publication number
AU2006326727A1
AU2006326727A1 AU2006326727A AU2006326727A AU2006326727A1 AU 2006326727 A1 AU2006326727 A1 AU 2006326727A1 AU 2006326727 A AU2006326727 A AU 2006326727A AU 2006326727 A AU2006326727 A AU 2006326727A AU 2006326727 A1 AU2006326727 A1 AU 2006326727A1
Authority
AU
Australia
Prior art keywords
single chain
bispecific single
cells
chain antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006326727A
Other languages
English (en)
Inventor
Patrick Baeuerle
Matthias Klinger
Peter Kufer
Eugen Leo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of AU2006326727A1 publication Critical patent/AU2006326727A1/en
Assigned to AMGEN RESEARCH (MUNICH) GMBH reassignment AMGEN RESEARCH (MUNICH) GMBH Alteration of Name(s) of Applicant(s) under S113 Assignors: MICROMET AG
Priority to AU2013202375A priority Critical patent/AU2013202375B2/en
Priority to AU2013202905A priority patent/AU2013202905A1/en
Priority to AU2017200512A priority patent/AU2017200512A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006326727A 2005-12-16 2006-11-29 Means and methods for the treatment of tumorous diseases Abandoned AU2006326727A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2013202375A AU2013202375B2 (en) 2005-12-16 2013-04-03 Means and Methods for the Treatment of Tumorous Diseases
AU2013202905A AU2013202905A1 (en) 2005-12-16 2013-04-08 Means and Methods for the Treatment of Tumorous Diseases
AU2017200512A AU2017200512A1 (en) 2005-12-16 2017-01-25 Means and Methods for the Treatment of Tumorous Diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05027606 2005-12-16
EP05027606.2 2005-12-16
EP06004144 2006-03-01
EP06004144.9 2006-03-01
PCT/EP2006/011466 WO2007068354A1 (en) 2005-12-16 2006-11-29 Means and methods for the treatment of tumorous diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2013202375A Division AU2013202375B2 (en) 2005-12-16 2013-04-03 Means and Methods for the Treatment of Tumorous Diseases
AU2013202905A Division AU2013202905A1 (en) 2005-12-16 2013-04-08 Means and Methods for the Treatment of Tumorous Diseases

Publications (1)

Publication Number Publication Date
AU2006326727A1 true AU2006326727A1 (en) 2007-06-21

Family

ID=37944802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006326727A Abandoned AU2006326727A1 (en) 2005-12-16 2006-11-29 Means and methods for the treatment of tumorous diseases

Country Status (15)

Country Link
US (3) US8007796B2 (enExample)
EP (1) EP1976886B1 (enExample)
JP (2) JP5442998B2 (enExample)
AU (1) AU2006326727A1 (enExample)
CA (1) CA2633594C (enExample)
CY (1) CY1116041T1 (enExample)
DK (1) DK1976886T3 (enExample)
ES (1) ES2532124T3 (enExample)
HR (1) HRP20150175T1 (enExample)
PL (1) PL1976886T3 (enExample)
PT (1) PT1976886E (enExample)
RS (1) RS53905B1 (enExample)
RU (1) RU2008129080A (enExample)
SI (1) SI1976886T1 (enExample)
WO (1) WO2007068354A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3136727B2 (ja) 1992-01-13 2001-02-19 日本電気株式会社 適応フィルタ制御方法
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
AU2006326727A1 (en) * 2005-12-16 2007-06-21 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
HRP20140331T1 (hr) 2006-08-14 2014-05-09 Xencor, Inc. Optimizirana antitijela usmjerena na cd19
US20110262440A1 (en) 2008-11-07 2011-10-27 Micromet Ag Treatment of pediatric acute lymphoblastic leukemia
CA2742249C (en) 2008-11-07 2020-07-21 Micromet Ag Treatment of acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody
SI2493503T2 (sl) * 2009-10-27 2021-04-30 Amgen Research (Munich) Gmbh Režim odmerjanja za dajanje cd19xcd3 bispecifičnega protitelesa
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
DK2632954T4 (da) 2010-10-27 2021-08-09 Amgen Res Munich Gmbh Midler og fremgangsmåder til behandling af dlbcl
SMT201700250T1 (it) 2010-11-10 2017-07-18 Amgen Res Munich Gmbh Prevenzione di effetti avversi provocati da domini leganti cd3 specifici
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
EP2701741B1 (en) 2011-04-28 2020-06-10 Amgen Research (Munich) GmbH Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
US9486475B2 (en) 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
ES2960807T3 (es) 2013-10-11 2024-03-06 Us Health Anticuerpos contra TEM8 y su uso
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
FI3531133T3 (fi) 2014-05-30 2023-11-02 Amgen Res Munich Gmbh Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu
EP3875481B1 (en) 2014-11-14 2025-01-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CA3224507A1 (en) 2014-12-24 2016-06-30 Autolus Limited Cell co-expressing chimeric antigen receptors binding cd19 and cd22
CA3225013A1 (en) 2015-02-24 2016-09-01 Bioatla, Llc Conditionally active proteins
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
PT3271389T (pt) 2015-03-20 2020-05-13 Us Health Anticorpos neutralizantes dirigidos contra a gp120 e sua utilização
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
WO2017062748A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017079479A1 (en) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Neutralizing antibodies to hiv-1 gp41 and their use
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
EP3579848B1 (en) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
JP2021508477A (ja) * 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
WO2019136029A1 (en) 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
WO2019165122A1 (en) 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
WO2020132214A2 (en) 2018-12-20 2020-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
US20220204620A1 (en) 2019-04-30 2022-06-30 Amgen Research (Munich) Gmbh Means and methods for treating burkitt lymphoma or leukemia
EP3962523A2 (en) 2019-05-03 2022-03-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
JP2022539589A (ja) 2019-07-02 2022-09-12 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＥＧＦＲｖＩＩＩと結合するモノクローナル抗体およびその使用
EP4073122A4 (en) 2019-12-11 2024-03-27 Cullinan Oncology, Inc. ANTI-CD19 ANTIBODIES AND MULTI-SPECIFIC BINDING PROTEINS
EP4073114A4 (en) * 2019-12-11 2024-04-17 Cullinan Oncology, Inc. Anti-serum albumin antibodies
WO2021150824A1 (en) * 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP2023517889A (ja) 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
AR122018A1 (es) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y clec12a
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
AU2022221297A1 (en) 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
CA3210753A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
WO2023044272A1 (en) 2021-09-17 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
JP2025506172A (ja) 2022-02-10 2025-03-07 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ コロナウイルスを広く標的とするヒトモノクローナル抗体
US20250197483A1 (en) 2022-03-28 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
EP4565329A1 (en) 2022-08-01 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024138151A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
WO2024243355A1 (en) 2023-05-24 2024-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025024233A1 (en) 2023-07-21 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies that broadly target coronaviruses
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025117384A1 (en) 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025137284A2 (en) 2023-12-21 2025-06-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19725586C2 (de) * 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
WO1999054440A1 (en) * 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
WO2005007809A2 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
RU2005141512A (ru) 2003-05-31 2007-07-20 Микромет Аг (De) Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками
EP2292664B1 (en) 2003-10-16 2016-11-23 Amgen Research (Munich) GmbH Multispecific deimmunized CD3-binders
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
AU2006326727A1 (en) * 2005-12-16 2007-06-21 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
CA2742249C (en) * 2008-11-07 2020-07-21 Micromet Ag Treatment of acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody
US20220281997A1 (en) * 2019-09-27 2022-09-08 Nanjing GenScript Biotech Co., Ltd. Anti-VHH Domain Antibodies and Use Thereof

Also Published As

Publication number Publication date
DK1976886T3 (en) 2015-03-02
WO2007068354A1 (en) 2007-06-21
ES2532124T3 (es) 2015-03-24
EP1976886A1 (en) 2008-10-08
HK1116202A1 (en) 2008-12-19
US20090291072A1 (en) 2009-11-26
EP1976886B1 (en) 2014-12-17
RS53905B1 (sr) 2015-08-31
CA2633594A1 (en) 2007-06-21
JP5834056B2 (ja) 2015-12-16
HRP20150175T1 (en) 2015-03-27
US11154617B2 (en) 2021-10-26
PT1976886E (pt) 2015-03-09
PL1976886T3 (pl) 2015-06-30
JP5442998B2 (ja) 2014-03-19
US8007796B2 (en) 2011-08-30
CA2633594C (en) 2021-10-26
RU2008129080A (ru) 2010-01-27
WO2007068354A8 (en) 2007-08-09
JP2009519257A (ja) 2009-05-14
SI1976886T1 (sl) 2015-03-31
US20220088196A1 (en) 2022-03-24
JP2014028840A (ja) 2014-02-13
US20130095103A1 (en) 2013-04-18
CY1116041T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
US20220088196A1 (en) Means and Methods for Treating Tumorous Diseases
KR102595561B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
JP7126941B2 (ja) がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
JP2023109927A (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
CN110536905A (zh) 用于治疗肺癌的抗pd-1抗体
US20250340634A1 (en) Dosage regimens for anti-cd19 agents and uses thereof
JP2024537288A (ja) Ｃｄ１９結合ｔ細胞誘引抗体の皮下投与
AU2013202375B2 (en) Means and Methods for the Treatment of Tumorous Diseases
CN101331151A (zh) 治疗肿瘤性疾病的方式和方法
HK1116202B (en) Means and methods for the treatment of tumorous diseases
TW202539732A (zh) 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
HK1255040B (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted